Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03860207 · ClinicalTrials.gov registry record · Phase 1
Study of the Safety and Efficacy of Humanized 3F8 Bispecific Antibody (Hu3F8-BsAb) in Patients With Relapsed/Refractory Neuroblastoma, Osteosarcoma and Other Solid Tumor Cancers
A Phase 1 study, sponsored by Y-mAbs Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT03860207 is a Phase 1 study that was terminated before completion, run by Y-mAbs Therapeutics. The registered enrollment target is 12 participants.
The verdict
NCT03860207, a Phase 1 study, was terminated before completion, sponsored by Y-mAbs Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
The purpose of this study is to test the safety of a study drug called humanized 3F8 bispecific antibody (Hu3F8-BsAb).
Interventions
- OTHER Blood draw
- BIOLOGICAL Humanized 3F8 Bispecific Antibody
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2019-02-22 |
| Est. Completion | 2021-10-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03860207
The ClinicalTrials.gov registry entry for NCT03860207 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Y-mAbs Therapeutics, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Blood draw is the first listed.
NCT03860207 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03860207 about?
NCT03860207 is a clinical study titled "Study of the Safety and Efficacy of Humanized 3F8 Bispecific Antibody (Hu3F8-BsAb) in Patients With Relapsed/Refractory Neuroblastoma, Osteosarcoma and Other Solid Tumor Cancers". The purpose of this study is to test the safety of a study drug called humanized 3F8 bispecific antibody (Hu3F8-BsAb).
What is the current status of trial NCT03860207?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2019-02-22. Estimated completion is 2021-10-20.
What interventions are being tested in trial NCT03860207?
The interventions under investigation include: Blood draw (OTHER), Humanized 3F8 Bispecific Antibody (BIOLOGICAL).
Who is sponsoring clinical trial NCT03860207?
This trial is sponsored by Y-mAbs Therapeutics, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.